Toll-Like Receptor 2 Regulates Intestinal Inflammation by Controlling Integrity of the Enteric Nervous System

2013 ◽  
Vol 145 (6) ◽  
pp. 1323-1333 ◽  
Author(s):  
Paola Brun ◽  
Maria Cecilia Giron ◽  
Marsela Qesari ◽  
Andrea Porzionato ◽  
Valentina Caputi ◽  
...  
2020 ◽  
Vol 159 (1) ◽  
pp. 200-213.e8 ◽  
Author(s):  
Shadi S. Yarandi ◽  
Subhash Kulkarni ◽  
Monalee Saha ◽  
Kristyn E. Sylvia ◽  
Cynthia L. Sears ◽  
...  

2012 ◽  
Vol 142 (5) ◽  
pp. S-555-S-556
Author(s):  
Paola Brun ◽  
Chiara Pivatello ◽  
Ketty Moratelli ◽  
Marsela Qesari ◽  
Michele Borgognone ◽  
...  

2019 ◽  
Vol 316 (4) ◽  
pp. G446-G452 ◽  
Author(s):  
Simona E. Carbone ◽  
Nicholas A. Veldhuis ◽  
Arisbel B. Gondin ◽  
Daniel P. Poole

G protein-coupled receptors (GPCRs) are essential for the neurogenic control of gastrointestinal (GI) function and are important and emerging therapeutic targets in the gut. Detailed knowledge of both the distribution and functional expression of GPCRs in the enteric nervous system (ENS) is critical toward advancing our understanding of how these receptors contribute to GI function during physiological and pathophysiological states. Equally important, but less well defined, is the complex relationship between receptor expression, ligand binding, signaling, and trafficking within enteric neurons. Neuronal GPCRs are internalized following exposure to agonists and under pathological conditions, such as intestinal inflammation. However, the relationship between the intracellular distribution of GPCRs and their signaling outputs in this setting remains a “black box”. This review will briefly summarize current knowledge of agonist-evoked GPCR trafficking and location-specific signaling in the ENS and identifies key areas where future research could be focused. Greater understanding of the cellular and molecular mechanisms involved in regulating GPCR signaling in the ENS will provide new insights into GI function and may open novel avenues for therapeutic targeting of GPCRs for the treatment of digestive disorders.


2005 ◽  
Vol 73 (3) ◽  
pp. 1452-1465 ◽  
Author(s):  
Andreas Sturm ◽  
Klaus Rilling ◽  
Daniel C. Baumgart ◽  
Konstantinos Gargas ◽  
Tay Abou-Ghazalé ◽  
...  

ABSTRACT Although the probiotic Escherichia coli strain Nissle 1917 has been proven to be efficacious for the treatment of inflammatory bowel diseases, the underlying mechanisms of action still remain elusive. The aim of the present study was to analyze the effects of E. coli Nissle 1917 on cell cycling and apoptosis of peripheral blood and lamina propria T cells (PBT and LPT, respectively). Anti-CD3-stimulated PBT and LPT were treated with E. coli Nissle 1917-conditioned medium (E. coli Nissle 1917-CM) or heat-inactivated E. coli Nissle 1917. Cyclin B1, DNA content, and caspase 3 expression were measured by flow cytometry to assess cell cycle kinetics and apoptosis. Protein levels of several cell cycle and apoptosis modulators were determined by immunoblotting, and cytokine profiles were determined by cytometric bead array. E. coli Nissle 1917-CM inhibits cell cycling and expansion of peripheral blood but not mucosal T cells. Bacterial lipoproteins mimicked the effect of E. coli Nissle 1917-CM; in contrast, heat-inactivated E. coli Nissle 1917, lipopolysaccharide, or CpG DNA did not alter PBT cell cycling. E. coli Nissle 1917-CM decreased cyclin D2, B1, and retinoblastoma protein expression, contributing to the reduction of T-cell proliferation. E. coli Nissle 1917 significantly inhibited the expression of interleukin-2 (IL-2), tumor necrosis factor α, and gamma interferon but increased IL-10 production in PBT. Using Toll-like receptor 2 (TLR-2) knockout mice, we further demonstrate that the inhibition of PBT proliferation by E. coli Nissle 1917-CM is TLR-2 dependent. The differential reaction of circulating and tissue-bound T cells towards E. coli Nissle 1917 may explain the beneficial effect of E. coli Nissle 1917 in intestinal inflammation. E. coli Nissle 1917 may downregulate the expansion of newly recruited T cells into the mucosa and limit intestinal inflammation, while already activated tissue-bound T cells may eliminate deleterious antigens in order to maintain immunological homeostasis.


2010 ◽  
Vol 11 (1) ◽  
pp. 97-97 ◽  
Author(s):  
Mauricio F Farez ◽  
Francisco J Quintana ◽  
Roopali Gandhi ◽  
Guillermo Izquierdo ◽  
Miguel Lucas ◽  
...  

1996 ◽  
Vol 10 (5) ◽  
pp. 335-341 ◽  
Author(s):  
Keith A Sharkey ◽  
Edward J Parr

Since about the 1950s nerves in the wall of the intestine have been postulated to play a role in the pathogenesis of inflammatory bowel disease (IBD). Human and animal studies examining the role of nerves in intestinal inflammation are the focus of this review. Consideration is given to two possible ways that nerves are involved in IBD. First, nerves may play a role in the development or maintenance of inflammation through local release of transmitters. Second, once initiated (by whatever means), the processes of inflammation may disrupt the normal pattern of innervation and the interactions of nerves and their target tissues. Many of the functional disturbances observed in IBD are likely due to an alteration in the enteric nervous system either structurally through disruptions of nerve-target relationships or by modifications of neurotransmitters or their receptors. Finally, it appears that the enteric nervous system may be a potential therapeutic target in IBD and that neuroactive drugs acting locally can represent useful agents in the management of this disease.


2009 ◽  
Vol 10 (9) ◽  
pp. 958-964 ◽  
Author(s):  
Mauricio F Farez ◽  
Francisco J Quintana ◽  
Roopali Gandhi ◽  
Guillermo Izquierdo ◽  
Miguel Lucas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document